Development and validated of spectrophotometric methods for the determination of Selexipag (An anti-hypertensive agent)

Selexipag is used for the treatment of pulmonary arterial hypertension. Pulmonary arterial hypertension is a relatively rare disease with usually a poor prognosis requiring more treatment options to prolong long-term outcomes. Selexipag is a selective prostacyclin receptor agonist. Prostacyclin is a potent vasodilator with anti-proliferative, anti-inflammatory, and anti-thrombotic effects. New zero order and first derivative spectrophotometric methods have been proposed for the determination of Selexipag in pharmaceutical formulations. Selexipag obeys Beer-Lambert's law over the concentration range 10–60 μg/ml for all the above mentioned methods and all the methods are validated as per ICH guidelines.